Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Therapeutic strategies for COVID-19: progress and lessons learned
Abstract The coronavirus disease 2019 (COVID-19) pandemic has stimulated tremendous
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …
Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis, therapeutics and vaccines
The emergence of novel and evolving variants of SARS-CoV-2 has fostered the need for
change in the form of newer and more adaptive diagnostic methods for the detection of …
change in the form of newer and more adaptive diagnostic methods for the detection of …
A molnupiravir-associated mutational signature in global SARS-CoV-2 genomes
Molnupiravir, an antiviral medication widely used against severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), acts by inducing mutations in the virus genome during …
coronavirus 2 (SARS-CoV-2), acts by inducing mutations in the virus genome during …
Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19： a meta-analysis
Background The coronavirus disease (COVID-19) epidemic has not been completely
controlled. Although great achievements have been made in COVID-19 research and many …
controlled. Although great achievements have been made in COVID-19 research and many …
Therapeutic advances in COVID-19
Over 2 years have passed since the start of the COVID-19 pandemic, which has claimed
millions of lives. Unlike the early days of the pandemic, when management decisions were …
millions of lives. Unlike the early days of the pandemic, when management decisions were …
Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients
Background New treatments are needed to reduce the risk of progression of coronavirus
disease 2019 (Covid-19). Molnupiravir is an oral, small-molecule antiviral prodrug that is …
disease 2019 (Covid-19). Molnupiravir is an oral, small-molecule antiviral prodrug that is …
Structural biology of SARS-CoV-2: open the door for novel therapies
W Yan, Y Zheng, X Zeng, B He, W Cheng - Signal Transduction and …, 2022 - nature.com
Abstract Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) is the causative
agent of the pandemic disease COVID-19, which is so far without efficacious treatment. The …
agent of the pandemic disease COVID-19, which is so far without efficacious treatment. The …
Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis
Molnupiravir is an orally available antiviral drug candidate currently in phase III trials for the
treatment of patients with COVID-19. Molnupiravir increases the frequency of viral RNA …
treatment of patients with COVID-19. Molnupiravir increases the frequency of viral RNA …
Therapeutics for COVID-19
SS Toussi, JL Hammond, BS Gerstenberger… - Nature …, 2023 - nature.com
Vaccines and monoclonal antibody treatments to prevent severe coronavirus disease 2019
(COVID-19) illness were available within a year of the pandemic being declared but there …
(COVID-19) illness were available within a year of the pandemic being declared but there …
A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus
There is an urgent need for an effective, oral, direct-acting therapeutic to block transmission
of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and prevent progression …
of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and prevent progression …